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Abstract Congenital disorders of glycosylation (CDG) com-
prise a group of inborn errors of metabolism with abnormal
glycosylation of proteins and lipids. Patients with defective
protein N-glycosylation are identified in routine meta-
bolic screening via analysis of serum transferrin glyco-
sylation. Defects in the assembly of the dolichol linked
Glc3Man9GlcNAc2 glycan and its transfer to proteins
lead to the (partial) absence of complete glycans on
proteins. These defects are called CDG-I and are located
in the endoplasmic reticulum (ER) or cytoplasm. De-
fects in the subsequent processing of protein bound
glycans result in the presence of truncated glycans on
proteins. These defects are called CDG-II and the en-
zymes involved are located mainly in the Golgi appara-
tus. In recent years, human defects have been identified
in dolichol biosynthesis genes within the group of
CDG-I patients. This has increased interest in dolichol
metabolism, has resulted in specific recognizable clinical
symptoms in CDG-I and has offered new mechanistic
insights in dolichol biosynthesis. We here review its
biosynthetic pathways, the clinical and biochemical phe-
notypes in dolichol-related CDG defects, up to the for-
mation of dolichyl-P-mannose (Dol-P-Man), and discuss
existing evidence of regulatory networks in dolichol
metabolism to provide an outlook on therapeutic
strategies.
Biosynthesis of dolichol
All tissues in eukaryotic organisms contain dolichol metabo-
lites. In human, they occur as dolichol (Dol) or dolichyl-
phosphate (Dol-P), while also dolichol esters and dolichoic
acid have been identified, for example in bovine thyroid
(Steen et al 1984; Van Dessel et al 1993) and human brain
(Guan 2009). Apart from the well studied localization of Dol-
P in the endoplasmic reticulum for protein N-glycosylation,
almost all organelle membranes, such as Golgi, mitochondria
and lysosomes, contain dolichol metabolites. Very limited
knowledge is available on the function of dolichol metabolites
in these organelles, like a modulatory effect of Dol and Dol-P
on the physico-chemical properties of lipid bilayers as well as
a protective ‘shielding’ of cellular lipids against the oxidative
damage caused by ROS. Numerous reviews summarizing the
literature on the cellular role of dolichol and Dol-P are recom-
mended to interested readers (Chojnacki and Dallner 1988;
Bergamini et al 2004; Swiezewska and Danikiewicz 2005;
Cantagrel and Lefeber 2011; Surmacz and Swiezewska 2011).
In recent years, dolichol metabolism gained considerably
increased interest in the context of protein glycosylation due
to the identified physiological consequences of disruptions in
this process, especially in the congenital disorders of glyco-
sylation (CDG). Identification of such gene defects resulted in
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significant progress in understanding of the molecular back-
ground of dolichol biosynthesis, but still many questions
remain unsolved. In this section, we review the current knowl-
edge on the network of enzymatic interactions for production
of dolichol and its glycosylated metabolites.
The schematic presentation of the biosynthetic pathway
leading to the synthesis of Dol-P is shown in Fig. 1. Dolichol
in animals and yeast is considered as the end-product of the
mevalonate (MVA) pathway. In summary, condensation of
three acetyl-CoA molecules gives rise to 3-hydroxy-3-meth-
ylglutaryl-CoAwhich by HMG-CoA reductase (HMGR), the
enzyme considered as the regulatory point of the entire MVA
pathway, is converted into mevalonate. Combined activity of
three subsequent enzymes leads to synthesis of isopentyl
diphospate (IPP), the building block for isoprenoids. Further
condensation of three IPP molecules results in formation of
farnesyl diphosphate (FPP), which is considered as a critical
branch-point of the pathway. It serves as substrate for four
different pathways: squalene synthase that catalyzes the first
step leading to production of cholesterol, trans-
prenyltransferase involved in ubiquinone side-chain synthesis,
protein farnesyltransferase responsible for posttranslational
farnesylation of proteins and cis-prenyltransferase, the first
specific enzyme in dolichol biosynthesis pathway.
Cis-prenyltransferase in yeast and animals uses FPP as
starter and catalyzes its numerous subsequent condensations
with IPP molecules to form polyprenyl diphosphate of a
desired chain-length which in fact is a mixture of several
homologues. The range of the number of IPPs added is
species-dependent; in yeast the dolichol molecules contain
14–18 isoprene units (i.u.) (Quellhorst et al 1998), mammalian
cells synthesize longer chains composed of 18–21 units (Rip
et al 1985), plant roots produce a broad mixture of homo-
logues, e.g. dolichol of Arabidopsis is composed of 12 tomore
than 30 i.u. (Jozwiak et al 2013). In contrast, bacterial CPTs
produce a single end product whichmost often contains 11 i.u.
Polyprenyl diphosphate is then dephosphorylated by mono
and/or diphosphatases (Frank and Waechter 1998) and con-
verted to dolichol by polyprenol reductase (Cantagrel et al
2010) absent from prokaryotic cells. Dolichol is further
phoshorylated by a dolichol kinase (Shridas and Waechter
2006) and might then serve as the carrier for mannose and
glucose monosaccharides further used as donors in N-glyco-
sylation, O- and C-mannosylation and GPI anchor synthesis.
Moreover, Dol-P serves as carrier of theGlcNAc2Man9Glc3
oligosaccharide precursor for protein N-glycosylation. Dol-P-
Man is synthesized by Dol-P-Man synthase via the DPM1-3
protein complex in human (Maeda and Kinoshita 2008), while
yeast contains a single DPM1 protein. Dolichyl-P-glucose
(Dol-P-Glc) is produced by dolichyl-phosphate β-
glucosyltransferase (ALG5 in human) (Heesen et al 1994).
Synthesis of the DolPP-GlcNAc2Man9Glc3 starts on the cy-
toplasmic side of the ER and afterwards the intermediate
DolPP-GlcNAc2Man5 is flipped by RFT1 (Haeuptle et al
2008) into the ER lumen where assembly of oligosaccharide
chain is completed. Finally, the fully formed oligosaccharide
structure GlcNAc2Man9Glc3 is co-translationally transferred
to the asparagine residue of the growing polypeptide with
release of Dol-PP that is recycled (Kornfeld and Kornfeld
1985; Banerjee 2012). The literature on biosynthesis of the
Dol-PP-glycan has been presented in numerous excellent
reviews (Denecke and Kranz 2009, Aebi 2013, Breitling and
Aebi 2013).
Molecular mechanisms of dolichol biosynthesis
Human genes encoding enzymes involved in the synthesis of
dolichol (Fig. 1) are listed in Table 1.
Cis-prenyltransferase CPT, syn. dehydrodolichyl diphos-
phate synthase, DHDDS, is the first enzyme dedicated exclu-
sively to dolichol biosynthesis. It is a highly conserved en-
zyme that can be found in all animal species, as well as in
plants and bacteria. The biochemical and molecular charac-
teristic of these enzymes have been studied earlier (Liang et al
2002; Takahashi and Koyama 2006). The prokayotic genes
encoding cis-prenyltranfereses (syn. undecaprenyl diphos-
phate synthase, UDPS) have been cloned from numerous
bacteria, e.g. Micrococcus luteus (Shimizu et al 1998),
Escherichia coli and Haemophilus influenzae (Apfel et al
1999). Eukaryotic cis-prenyltransferases identified in Saccha-
romyces cerevisiae are encoded by the RER2 and SRT1 genes,
expression of which is differently controlled during cell
growth (Sato et al 1999; Schenk et al 2001b). It was shown
that two yeast isoforms demonstrate different subcellular lo-
calization and physiological role. Rer2p, constitutively
expressed enzyme, is localized to the ER and synthesizes
dolichol molecules with 14–17 isoprene units, whereas Srt1p
is mainly found in lipid particles (lipid bodies) and produces
long chain molecules comprised of 19–22 units similar to
mammalian dolichols (Sato et al 1999). Mechanism by which
individual CPT enzymes recognizes the prenyl chain lengths
of substrates and products are postulated by Takahashi and
Koyama (2006).
Through comparison of the yeastCPT sequences with plant
genomic sequences, a few plant homologous genes have been
cloned, e.g. two genes from Arabidopsis thaliana (Cunillera
et al 2000; Oh et al 2000, Kera et al 2012; Surmacz et al 2013)
and the presence of a multiple CPT gene families has been
confirmed in plants (Surmacz and Swiezewska 2011; Akhtar
2013). Similar analysis of sequence homology revealed a
single gene encoding human CPT/DHDDS (Shridas et al
2003; Endo et al 2003). The human enzyme was able to
complement the Rer2 yeast deletion mutant. The hCPT/
DHDDS gene comprises eight coding exons (Shridas et al
2003; Zelinger et al 2011), encoding a protein of 334 amino
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Fig. 1 Schematic presentation of the enzymatic network leading to
production of dolichol and its glycosylated metabolites. Indicated are
the biosynthesis-related genes (in italic), glycosylation pathways (gray
ovals) and mutations in the genes causative for particular CDGs (gray
boxes). All the enzymes involved in the synthesis of dolichol and its
glycosylated derivatives are located in the ER or cytoplasm
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acids (Shridas et al 2003; Endo et al 2003) and was mapped to
chromosome 1p36.11.
Overexpression of hCPT inmammalian cells results in only
slight increase of its enzymatic activity suggesting that an
accessory protein might be required for full activity of human
cis-prenyltransferase (Shridas et al 2003). This interesting
supposition has further been experimentally confirmed and
the molecular machinery responsible for regulation of hCIT
activity has been partially resolved by Harrisson et al (2011).
The authors identified Nogo-B receptor (NgBR) as compo-
nent modulating CPT activity and regulating dolichol biosyn-
thesis in mammalian cells. Previously, NgBR has been de-
scribed as a NPC2-binding protein (Nieman-Pick type 2) that
promotes NPC2 stability in the ER lumen. It was shown that
NgBR exists in two topological conformations. The minor
fraction with C-terminal end facing the luminal side of the ER
related to regulation of NPC2 stability (Harrison et al 2009)
while the major fraction with its C-terminal end oriented
towards the cytosol regulates CPT activity and binds hCPT
(Harrison et al 2011). Functional studies in the yeast mutant
rer2 revealed that NgBR is not sufficient to rescue its growth
phenotype and confirm that this protein is not an independent
single subunit enzyme but is rather necessary to maintain the
enzymatic activity of hCPT. Loss of NgBR expression results
in robust deficit in CPT activity and consequently undetect-
able levels of dolichol. Co-immunoprecipitation confirmed
that the C-terminal domain of NgBR is necessary for its
interaction with hCPT (Harrison et al 2009).
Polyprenyl (di)phosphate phosphatase Activity required to
dephosphorylate polyprenyl diphosphate has been reported
in several biological systems including yeast, mammals and
plants (Wedgwood and Strominger 1980; Adair and Cafmeyer
1983; Wolf et al 1991; Ravi et al 1983). The gene encoding
this (di)phosphatase activity is still unclear. The CWH8 gene
in Saccharomyces cerevisiae encodes a phosphatase capable
of converting Dol-PP to Dol-P and also at a slower rate is able
to dephosphorylate Dol-P (Fernandez et al 2001). This activity
is required after release of Dol-PP from the protein glycosy-
lation reaction for new rounds of glycosylation. Additionally,
two other genes encoding Mg2+-independent lipid phos-
phatases, LLP1 and DPP1, have been identified in
Saccharomyces with hydrolytic activities towards Dol-PP,
Dol-P, farnesyl-PP and geranylgeranyl-PP (Faulkner et al
1999). DOLPP1, the mammalian ortholog of yeast CWH8
shares a high degree of sequence identity with the yeast
enzyme (Rush et al 2002) and is able to complement defects
in growth, protein N-glycosylation and accumulation of Dol-
PP in the cwh8 mutant yeast cells. Mouse polyprenyl phos-
phate phosphatase is comprised of 238-amino acids, contains
four putative transmembrane domains and possesses a con-
sensus lipid-phosphate phosphatase motif. The N- and C-
termini are predicted to be on the cytosolic face of the ER,
and the catalytic domain is predicted to be on the luminal face
of the ER (Rush et al 2002). Radiation hybrid analysis and
FISH revealed that human DOLPP1 (also termed LSFR2) is
located on chromosome 9q34.1 (Gilley and Fried 1999) and
comprises eight exons. No details are available on its
structure-function studies in human cells.
Polyprenol reductase Polyprenol reductase produces dolichol
by reduction of the α-terminal isoprene residue of polyprenol.
Biochemical characterization of polyprenol reductase of rat
liver and yeast has been presented earlier (Sagami et al 1993;
Tateyama and Sagami 2001), while the first identification of
the gene encoding polyprenol reductase has been achieved in
human by Cantagrel et al (2010). They showed that SRD5A3
is essential for protein N-linked glycosylation in mammals
(Cantagrel et al 2010). The yeast polyprenol reductase is
encoded by the DFG10 gene. Expression of human SRD5A3
in the dgf10 mutant yeast cells rescued the phenotype of
Table 1 Genes encoding enzymes involved in dolichol biosynthesis in human
Gene Enzyme Other names GenBank number Locus
DHDDS cis-prenyltransferase dehydrodolichyl diphosphate synthase NM_024887 1p35.3
NUS1 Nuclear undecaprenyl pyrophosphate
synthase 1 homolog
Nogo-B receptor (NgBR) NM_138459 6q22.1
DOLPP1 mono/ diphosphatase dolichyl pyrophosphate phosphatase 1 NM_020438 9q34.1
SRD5A3 polyprenol reductase steroid 5 alpha-reductase 3 NM_024592.4 4q12
DOLK dolichol kinase NM_014908 9q34.13
Table 2 Diagnostic clinical clues in dolichol cycle defects
Characteristic symptoms Gene
Ichthyosiform skin MPDU1, DOLK,
SRD5A3
Dilated cardiomyopathy DOLK, DPM3
Muscle dystrophy and/or increased CK DPM1, DPM2,
DPM3
Non-syndromal retinitis pigmentosa DHDDS
Ocular abnormalities (coloboma, glaucoma,
cataract, optic atrophy)
SRD5A3
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carboxypeptidase Y (CPY) underglycosylation and partially
decreased the accumulation of polyprenols. In Arabidopsis,
the presence of two SRD5A3-LIKE genes has been postulated
(Jadid et al 2011; Jozwiak et al unpublished data).
In human, a single gene encoding polyprenol reductase is
located on chromosome 4p12 and contains five exons encoding
a protein of 318 amino acids. The SRD5A3 protein has six
transmembrane domains and is localized in the endoplasmatic
reticulum (ER) and endoplasmic reticulum-Golgi intermediate
compartment (ERGIC). The structure of polyprenol reductase
has not been described yet. SRD5A3 has been considered so far
as a member of the 5α-steroid reductase family and its involve-
ment, along with SRD5A1 and −2, in reduction of testosterone
to dihydroteststerone is shown in several systems (Uemura et al
2008; Mitsiades et al 2012; Titus et al 2014). However, the
recent data on SRD5A3 function in polyprenol reduction ques-
tions the role of steroids as endogenous substrates.
Analysis of SRD5A3 expression identified the transcript of
this gene in virtually all human tissues: brain, kidney, liver,
stomach, pancreas, hearth, placenta, spleen, duodenum, colon,
breast, thyroid, tonsil, skin and also cancer cell lines
(Kazutoshi et al 2008; Uemura et al 2008; Morava et al
2010; Godoy et al 2011; Azzouni et al 2012). The hydropho-
bic N-terminal region, probably responsible for interaction
with the substrates, and the H296 residue located in the
catalytic domain of SRD5A3 could have critical roles for its
androgen-producing activity, since this activity is abolished by
mutations at both sites (Uemura et al 2008). Homozygous
nonsense mutations in the SRD5A3 gene leading to early
truncated protein were found in SRD5A3-CDG patients. This
resulted in polyprenol accumulation and normal or increased
levels of dolichols in plasma and tissues of patients (Cantagrel
et al 2010). Reduced levels of dolichol and its derivative Dol-
P are supposed to affect N-glycosylation of proteins, suggest-
ing that only the local pool of Dol-P in the ER is limiting, and
results in a congenital disorders of glycosylation type I (CDG
I) (Cantagrel et al 2010; Lefeber et al 2011). Clearly, an
alternative pathway for dolichol synthesis must be present in
yeast, mouse and human to account for residual dolichol in
these null-mutants. Potentially, the oxidative pathway invol-
ving dolichal could play such a role (Sagami 1996). It has been
shown that deletion of the SRD5A3 gene in mice disrupted
protein glycosylation and resulted in death of mouse embryos
at embryonic day 12.5 (Cantagrel et al 2010). SRD5A3 in-
volvement in cellular processes has recently been reviewed
(Cantagrel and Lefeber 2011; Azzouni et al 2012; Traish 2012).
Dolichol kinase Dolichol kinase catalyzes the CTP-mediated
phosphorylation of dolichol (Fernandez et al 2002). In yeast,
dolichol kinase is encoded by SEC59 (Heller et al 1992). One
gene encoding a putative dolichol kinase was found in the
Arabidopsis thaliana genome [BLASTP screen], while bio-
chemical characterization of DOLK has been performed in
soybean (Rip and Carroll 1988). A bacterial enzyme was
purified from Lactobacillus (Kalin and Allen 1979). Human
dolichol kinase has been characterized at the molecular level
by the group of Waechter (Fernandez et al 2002; Shridas and
Waechter 2006). Human DOLK (DK1) is located on chromo-
some 9 (Kikuno et al 1999). The open reading frame encodes
a protein with 538 amino acids. Highest expression levels of
DOLKmRNAwas observed in fetal and adult brain, followed
by fetal skeletal muscle and heart and adult heart tissue
(Lefeber et al 2011). Dolichol kinase is a hydrophobic protein
with 13 membrane-spanning domains (Shridas and Waechter
2006). However, Haeuptle and Hennet (2009) predicted 15
transmembrane domains. Structure-function studies indicate
that the C-terminal domain exposed to the cytoplasmic face
contains a CTP-binding pocket. Deletion of this region or
mutation of conserved residues (K470/471 and T472) within
this motif results in a partial or total loss of activity and altered
affinity for CTP. What is more, G320D substitution in the
mutated enzyme of yeast cells was found. Conversion of the
corresponding residue G443D in human dolichol kinase abol-
ish its activity (Shridas and Waechter 2006).
Dolichol cycle
By phosphorylation of dolichol, the dolichol kinase enables
the transfer of monosaccharides to Dol-P and the initiation of
dolichol-linked oligosaccharide biosynthesis. This process
takes place on both sites of the ER membrane and requires
the activity of several specific glycosyltransferases. The
monosaccharides added to the growing lipid linked oligosac-
charide (LLO) are derived from nucleotide-activated donors
or from Dol-P-linked monosaccharides. UDP-GlcNAc and
GDP-Man serve as substrates for the transferases that act on
the cytoplasmic side of the ER membrane, whereas Dol-P-
linked sugars are substrates for lumenal glycosyltransferases.
Since enzymes participating in the synthesis and modification
of the LLO and respective genes have been described in
numerous excellent reviews (e.g. Haeuplte and Hennet 2009;
Banerjee 2012; Aebi 2013; Breitling and Aebi 2013), only a
brief summary on selected steps of the LLO pathway is
presented below.
Dol-P-Man is utilized as a substrate for N-glycosylation,
O-mannosylation of proteins (Lommel and Strahl 2009) and
biosynthesis of GPI-anchored proteins (Orlean and Menon
2007). Dol-P-Man is generated from Dol-P and GDP-
mannose by the Dol-P-Man synthase, which in humans forms
an oligomeric enzyme complex comprised of DPM1, DPM2
and DPM3 (Maeda et al 2000). DPM1 is the catalytic com-
ponent associated with DPM3 and DPM2 that is required to
target cytosolic DPM1 to the ER membrane. The structural
characteristics of the mammalian Dol-P-Man synthase com-
plex and the roles of individual subunits has been described
(Maeda and Kinoshita 2008).
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It is also worth noting that MPDU1, a membrane protein
localized in the ER, is essential for the use of Dol-P-Man and
Dol-P-Glc in GPI and LLO biosynthesis and protein O-, C-
mannosylation although its precise function is unclear (Anand
et al 2001).
Monosaccharides and oligosaccharide chains carried on
Dol-P are necessary for different glycosylation pathways and
require sufficient amounts of Dol-P. To provide an ad-
equate cellular concentration of Dol-P, de novo synthesis is
assisted by the recycling pathway. An essential step in this
recycling is the conversion of Dol-PP, released by the
oligosaccharyltransferase, to Dol-P by diphosphatase that acts
at the luminal side of the ER. In yeast, this reaction is cata-
lyzed by the CWH8 phosphatase and in human by DOLPP1.
It is as yet unclear if DOLPP1 can also dephosphorylate
polyprenyl-PP during polyprenol synthesis. An additional
appealing issue for clarification is how Dol-P flips across the
ER membrane for new rounds of Dol-PP-glycan synthesis,
because no potential Dol-P flippase has been described to
date. A potential mechanism for translocation of Dol-P is
discussed by Breitling and Aebi (2013).
Dolichol-related human disease phenotypes
As discussed above, dolichol and its metabolites perform
pleiotropic functions in cellular systems and the clinical symp-
toms that result from genetic deficiencies in its biosynthesis
are not easily predicted. The identification of dolichol biosyn-
thesis defects within the group of CDG-I patients has allowed
us to start correlating clinical symptoms with biochemical
pathways. The classical presentation of CDG-I defects is a
multi-organ disease with neurological involvement. A few
subtypes without neurological symptoms, such as MPI-
CDG, have also been observed. The metabolic pathway re-
quired for synthesis of the Glc3Man9GlcNAc2-PP-dolichol
precursor in the ER is identical in each eukaryotic cell and,
as a dogma, all N-glycosylated proteins are similarly affected
resulting in a multisystem disease. In practice, the situation is
more subtle with some proteins being more severely affected
than others. For example, lack of complete N-glycans on
intercellular adhesion molecule-1 (ICAM1) result in its ab-
sence on the plasma membrane, whereas other proteins can be
normally secreted but have defective function. The conse-
quences are different for a defect in sugar supply pathways,
such as the availability of the sugar donor Dol-P-Man, as these
defects are not restricted to N-glycosylation. Other glycosyl-
ation pathways executed in the ER including C- and O-
mannosylat ion, GPI-anchor biosynthesis and O-
glucosylation also depend on available dolichol. In addition,
other cellular functions depending on the availability of
dolichol metabolites might be disturbed. In this section, we
will review the currently known genetic diseases in such
”shared” pathways and discuss the current understanding of
specific clinical symptoms in relation to different glycosyla-
tion pathways, especially dystroglycan O-mannosylation (we
also refer to previous reviews of Denecke and Kranz 2009;
Cantagrel and Lefeber 2011 and Wolfe et al 2012). Table 2
summarizes characteristic clinical symptoms that can occur
(more or less) isolated or in combination with other symptoms
in a multisystem presentation.
DHDDS-CDG (MIM 613861) Cis-prenyltransferase
(DHDDS) is the first commited step in Dol-P biosynthesis.
Thus far, no patients with abnormal N-glycosylation have been
reported with a defect in DHDDS. However, the K42E and
T206A missense mutations have been linked to autosomal
recessive nonsyndromal retinitis pigmentosa (RP) (Zelinger
et al 2011; Zuchner et al 2011; Wen et al 2013). In plasma
and urine of patients, a characteristic shortening of dolichols
was identified by mass spectrometry (Wen et al 2013). Instead
of the common dolichol-19 species, dolichol-18 was the dom-
inant species in patients. Interestingly, no significant abnormal-
ity in protein glycosylation has been observed of plasma trans-
ferrin in deficient patients. Suppression of DHDDS expression
in zebrafish leads to the loss of photoreceptor outer segments
and visual function. These observations support the hypothesis
that insufficient DHDDS function leads to retinal degeneration
(Wen et al 2014). Still the cellular mechanisms explaining
whether and how the shortened dolichol profiles contribute to
the retinal degeneration phenotype awaits clarification.
NUS1-CDG (no MIM entry yet) NUS1, encoding the NogoB
receptor is essential for cis-prenyltransferase activity and is
known to bind to the NPC2 protein, involved in cholesterol
metabolism. Recently, a homozygous missense mutation was
identified in NUS1 in two siblings (Park et al 2014). Patients
presented with scoliosis, severe epilepsy, muscle hypotonia,
developmental delay, microcephaly, and visual impairment.
Cholesterol in plasma was normal but increased in patient
fibroblasts. In fibroblasts, incorporation of mannose in glyco-
proteins was reduced and LAMP1 and ICAM1 seemed to be
hypoglycosylated. In plasma and urine, the dolichol chain
length shifted to shorter lengths in a patient and also slightly
in two analyzed heterozygous carriers, with dolichol-19 being
most abundant in controls and dolichol-18 in the patient. No
mention was made of dilated cardiomyopathy, increase of
creatine kinase or skin involvement, as seen in other CDG
subtypes discussed in this review.
SRD5A3-CDG (MIM 612379) Polyprenol reductase is need-
ed for conversion of polyprenol to dolichol. Mutations in
steroid 5α-reductase type 3 encoding gene (SRD5A3) lead to
a purely neurological disease with developmental delay, ataxia
and early visual impairment with optic atrophy (Cantagrel
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et al 2010; Morava et al 2010). Prominent ocular abnormali-
ties were observed with retinal coloboma, congenital cataract
and glaucoma. In addition, ichthyosiform dermatitis was re-
ported with liver dysfunction and coagulation abnormalities.
None of the patients presented with muscle or heart pathology.
Two adult patients (∼40 years old) were recently described
with an isolated presentation of ataxia (Kara et al 2014).
Analysis of polyisoprenoids in SRD5A3-CDG patient
plasma by mass spectrometry (Cantagrel et al 2010) revealed
an increase of the concentration of polyprenols, which facili-
tates diagnosis. In patient cells, no clear abnormalities could
be observed of polyprenols and dolichols. In dfg10 knock-out
yeast, however, polyprenol accumulation was observed with a
concomitant considerable decrease in levels of dolichol. Inter-
estingly, irrespective of early truncating mutations in all pa-
tients, dolichol was still present in plasma and cells of patients.
This lead to the suggestion of the presence of an additional
protein involved in polyprenol reduction (Cantagrel et al
2010). It could well be that the presence of such an alternative
pathway explains the absence of muscle dystrophy and/or
dilated cardiomyopathy in SRD5A3-CDG patients.
DOLK-CDG (MIM 610768) Dolichol kinase is required for
phosphorylation of dolichol. Dol-P serves as precursor for
synthesis of Dol-P-Man by Dol-P-Man synthase and Dol-P-
Glc by ALG5 but also serves as anchor for the
Glc3Man9GlcNAc2 glycan. The first description of four patients
with mutations in DOLK (Kranz et al 2007) revealed a very
severe phenotype with early death. Characteristic symptoms
were dilated cardiomyopathy, muscular hypotonia, and
ichthyosiform abnormalities of the skin. Involvement of Dol-
P in multiple pathways, additionally to glycosylation, was
suggested to be related to the peculiar clinical phenotype. A
subsequent study (Lefeber et al 2011) revealed a milder course
of disease in 11 patients with a presentation dominated by
dilated cardiomyopathy. In addition, ichthyosis was noted in
several patients without significant muscular weakness or ele-
vation of creatine kinase. In heart muscle, abnormal O-
mannosylation of alpha-dystroglycan was found, which was
suggested to be correlated with the occurrence of dilated car-
diomyopathy (DCM). Two additional case reports showed a
multisystem presentation, including DCM, epilepsy and dys-
morphic features (Lieu et al 2013) in one patient and a purely
neurological presentation in a sib-pair (Helander et al 2013)
without the occurrence of heart or skeletal muscle problems.
DPM-CDG (DPM1: MIM 608799 ; DPM2: MIM 615042 ;
DPM3: MIM 612937) Dol-P-Man synthase is required for
synthesis of Dol-P-Man and is composed of three subunits
(DPM1-3). Early fatal disease causing mutations were first
described for the catalytic subunit DPM1 (Imbach et al 2000;
Kim et al 2000). Patients presented with severe congenital
visual loss, optic atrophy and seizures. A milder course was
later observed in a 9-year old patient with mild dysmorphic
features, developmental delay, microcephaly, optic atrophy,
cerebellar dysfunction and elevated creatine kinase (Garcia-
Silva et al 2004). Dancourt et al (2006) reported a brother and
sister with a presentation dominated by ataxia, with normal
creatine kinase. The overall presentation of DPM1-CDG was
interpreted as the characteristic multisystem phenotype of
CDG-I defects. In 2009, a homozygous mutation was identified
in DPM3 in a young woman who presented with muscle
weakness due to muscular dystrophy as diagnosed after muscle
biopsy and a dilated cardiomyopathy (Lefeber et al 2009).
These particular symptoms were not known for CDG-I N-
glycosylation defects. Further studies revealed abnormal O-
mannosylation of alpha-dystroglycan in amuscle biopsy, which
linked CDG with the dystroglycanopathies, a subgroup of the
congenital muscular dystrophies. Patients with a
dystroglycanopathy present with muscle dystrophy, while di-
lated cardiomyopathy has been reported in several milder cases
(Pane et al 2012). Expression of the GPI-anchored protein
CD59 on fibroblasts and C-mannosylation of serum properdin
were normal. DPM2-CDG (Barone et al 2012) was described in
three infantile patients with profound developmental delay,
intractable epilepsy and severe hypotonia with elevated blood
creatine kinase levels. Abnormal O-mannosylation was con-
firmed in a muscle biopsy. For DPM1-CDG, abnormal O-
mannosylation in muscle was recently described (Yang et al
2013) in a patient with severe motor delay and elevated creatine
kinase. Although it cannot be excluded that other glycosylation
pathways are also affected and contribute to the clinical presen-
tation in more severely affected patients, the current data sug-
gest that the clinical symptoms in Dol-P-Man synthase defects
are correlated with abnormal N-glycosylation and O-
mannosylation.
MPDU1-CDG (MIM) MPDU1 is required for utilization of
the Dol-P-Man and Dol-P-Glc donors in ER glycosylation
reactions, although the exact mechanism of action remains
unsolved. Only very few patients with MPDU1-CDG have
been reported (Schenk et al 2001a; Kranz et al 2001). Patients
presented with psychomotor retardation, epilepsy and skin
disease, including ichthysosis.
Outlook to new genes and CDG subtypes
Identification of novel gene defects in dolichol metabolism
has already provided novel insights in biochemistry and clin-
ical symptoms, but novel findings are to be expected. More
severe mutations in DHDDS could very well result in a
multisystem phenotype, including symptoms of CDG-I,
ichthyosis and the dystroglycanopathies and an abnormal type
I transferrin isofocusing profile. For DOLPP1, no genetic
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defect has been reported to date. Its role is primarily located in
the recycling of Dol-P after N-glycosylation, which would
suggest a likely multisystem phenotype as in other CDG-I
defects. Nevertheless, this could as well result in diminished
levels of Dol-P as in DOLK-CDG, which could give rise to
clinical symptoms such as muscle dystrophy, ichthyosis and
dilated cardiomyopathy. The occurrence of ichthyosis is lim-
ited to the dolichol biosynthesis defects SRD5A3-CDG and
DOLK-CDG, but also occurs in MPDU1-CDG and not in
DPM-CDG. This might hint to a direct role ofMPDU1 in lipid
metabolism. Possibly, this could include the utilization of Dol-
P apart from its confirmed role in utilization of Dol-P-Man
and Dol-P-Glc (Anand et al 2001). Finally, for some of the
biochemical steps in dolichol metabolism, genes still have to
be identified, for example the possible flipping of Dol-P from
ER to cytosol, the dephosphorylation of polyprenyl-PP during
biosynthesis and the alternative pathway for polyprenol re-
duction. Identification of such additional gene defects in
dolichol metabolism and detailed clinical characterization will
help to solve issues like tissue specific biochemical mecha-
nisms and the flux through dolichol biosynthesis towards
different glycosylation pathways.
Opportunities for overcoming defects in dolichol
biosynthetic pathways
A facile approach towards therapeutic strategies in dolichol
cycle defects would be to replenish the missing substrates
dolichol or Dol-P (Jakobsson et al 1989; Kalen et al 1990).
However, the contribution of dietary dolichol metabolites to
the cellular pool of dolichol for glycosylation reactions seems
to be very limited, as shown experimentally and reviewed
(Cantagrel et al 2011). Strategies to target dolichols to the site
of glycosylation in the ER would circumvent this problem.
Although most of the biosynthetic steps have been character-
ized at the molecular level, knowledge about the regulation of
particular enzymes remains scarce with one exception, namely
HMGR, the most studied enzyme in literature. Additionally,
nothing is known about networking and global regulation of
the dolichol pathway. In this section, we aimed to summarize
the literature on regulatory mechanisms modulating the activ-
ity of dolichol synthesizing enzymes and consequently affect-
ing the cellular levels of dolichol metabolites, which might
provide future opportunities to improve dolichol availability
for protein glycosylation.
Regulation of cis-prenyltransferase (CPT)
Data on the factors regulating activity of CPT are limited. So
far only a few observations have been published and no
regulatory network has been suggested.
A pleiotropic stimulator cAMP increases the activity of
human cis-prenyltransferase as shown by a tenfold increase
of CPT activity in human placenta choriocarcinoma (JEG-3)
cells, pretreated with 8-bromo-cAMP. This is in line with a 60-
and 20-fold enhancement of de novo synthesis of dolichol and
dolichyl phosphate, respectively. These results have been
substantiated by the induction of hCPT activity in a cAMP-
generating system (activation of adenylate cyclase by
forskolin in the presence of phosphodiesterase inhibitor
IBMX). Stimulation of the dolichol/Dol-P pathway by cAMP
seems specific since biosynthesis of cholesterol has not been
stimulated upon the same conditions (Konrad and Merz
1996). A more recent study implicates protein kinase PKA
type I in the modulation of cAMP-mediated regulation of
protein N-glycosylation. Moreover Dol-P-Man synthase is
postulated as the main target of PKA I (Banerjee 2007).
CPT activity is modulated in response to developmental
changes since Dol-P level increases linearly through the cell
cycle in mouse L-1210 cells, reaching twofold increase in S
phase in comparison to early G1. Consistently, cis-
prenyltransferase activity is increasing through G1 to a max-
imum level in the S phase (Adair and Cafmeyer 1987). Like-
wise, a concomitantly increased activity of rat CPT and LLO
synthesis was noted in the S phase of synchronized cultures of
rat 3Y1 cells (Fukushima et al 1997). Finally, in vitro CPT
activity measurement using rat liver microsomes reveals a low
level after birth which increases continuously up to day 54 and
then decreases to a low level maintained throughout the re-
mainder of the study (365 days). Simultaneous monitoring of
dolichol concentrations in rat liver indicates a continuous
increase throughout the entire period in contrast to the con-
stant level of cholesterol (Thelin et al 1994).
On the other hand, an age-related accumulation of dolichol
is postulated to be linked to a higher availability of
mevalonate, which is linked to an increased activity of HMGR
due to the loss of enzymatic regulation (Pallottini et al 2003).
A large increase of CPT activity (15-fold) and increased
Dol-P synthesis is noted during the proliferative response of
murine B lymphocytes (B cells) to bacterial lipopolysaccha-
ride (LPS) (Crick et al 1994).
Modulation of expression of CPT encoding genes has been
observed in plants. Transcription and activity of LlCPT (iden-
tified in Lilium longiflorum anther-66) is regulated during
microspore development in the anther, while additionally the
expression of LLA66 is regulated by plant hormones, gibberel-
lin and ethylene (Liu et al 2011). Increased expression of
AtCPT6 (also called heptaprenyl diphosphate synthase
AtHEPS) is caused by cold treatment of Arabidopsis seedlings
(Kera et al 2012). Sugar type (glucose or sucrose ) and concen-
tration modulate the expression level of all six AtCPTencoding
genes detected in A. thaliana hairy roots (Jozwiak et al 2013).
A few interesting but not fully explored observations indi-
cate the involvement of various genes/proteins in regulation of
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CPT activity. This might shed light on the cellular network of
CPT in diverse biological systems. For example, an interac-
tion was detected of hCPT with the Niemann–Pick type C2
protein (NPC2) via a yeast two-hybrid screen, which was
confirmed by in vitro co-immunoprecipitation experiments.
This suggested a putative involvement of NPC2 in regulation
of hCPT and dolichol biosynthesis (Kharel et al 2004).
Nogo-B receptor (NgBR), known to bind NPC2 (Harrison
et al 2009), was suggested as modulator of CPT activity in
mammalian cells (Harrison et al 2011) — see above for
details. In vitro studies using rat liver microsomes show
that rCPT activity is stimulated sevenfold in the presence
of sterol carrier protein-2 with no appreciable effect on
polyprenol reductase, dolichol kinase or dolichyl phos-
phate phosphatase (Ericsson et al 1991).
Studies in Saccharomyces cerevisiae revealed a putative
role of YTA7 in the dolichol biosynthetic pathway since
deletion of YTA7 affected the enzymatic activity of cis-
prenyltransferase and the cellular levels of isoprenoid com-
pounds (Kuranda et al 2009).
Regulation of dolichol kinase, dolichyl phosphate
phosphatase and polyprenol reductase
First evidence for the developmental regulation of dolichol
kinase activity originate from the finding of twofold increased
activity in prenatal pig brains as compared to adult animals
with unchanged activity of dolichyl phosphate phosphatase
(Scher et al 1985). As mentioned for CPT, also the activity for
dolichol kinase and dolichyl phosphate diphosphatase showed
cell-cycle dependence (Adair and Cafmeyer 1987). Addition-
ally, environmental factors were found to modulate Dol-P
levels. Ethanol treatment resulted in decreased levels of Dol-
P (approx. 80% of the control) but did not alter DOLK tran-
script levels in HepaRG cells (Welti and Hülsmeier 2014). In
line with decreased Dol-P levels, a smaller fraction of the final
oligosaccharide precursor Dol-PP-GlcNAc2Man9Glc3 (77%
of the control) has been observed (Welti and Hülsmeier
2014). Estrogens induce dolichol kinase activity due to an
increased level of the DOLK enzyme (Burton et al 1981).
Finally, dolichol kinase from rat brain and protozoa Tetrahy-
mena pyriformis was shown to be regulated by a system
involving calmodulin/Ca2+ (Gandhi and Keenan 1983).
Polyprenol reductase Data on regulation of polyprenol reduc-
tase SRD5A3 are very limited. It was shown that androgen
(dihydrotestosterone) regulates the mRNA level of SRD5A1,
−2 and −3 isoenzymes in a cell type–specific manner. It was
shown that regulation occurs at the transcriptional level and
that androgen receptor is recruited to a negative androgen
response element (nARE) on the promoter of SRD5A3
in vivo and directly binds to the nARE in vitro in LNCaP
prostate cancer cells (Li et al 2011). This observation is
consistent with SRD5A3 overexpression noted in hormone-
refractory prostate cancers in which the androgen level is low
(Uemura et al 2008). These data, however, do not confirm the
role of SRD5A3 in the biosynthesis of androgens.
Modulation of the polyisoprenoid profile upon particular
physiological conditions has been observed in yeast and
plants. An increased concentration of long-chain polyprenols
rather than dolichols was noted in S. cerevisiae mutants (mu-
tations in genes encoding farnesyl diphosphate synthase or
squalene synthase) for which a significant increase of CPT
activity in the late logarithmic phase was observed. Upon such
circumstances, polyprenol reductase seems to become ineffi-
cient (Szkopinska et al 2006).
Recently, modulation of the ratio of polyprenols versus
dolichols has been noted in response to sugar in Arabidopsis
hairy root cultures. In the family of long-chain polyisoprenoid
alcohols (Dol/Pren-23 dominating), polyprenols are dominat-
ing at 3% sucrose and dolichols at 2% glucose (Jozwiak et al
2013). These observations, although indirect, indicate the
existence of a cellular machinery responsible for regulation
of polyprenol reductase in response to various stimuli.
Regulation of LLO synthesis
The availability of Dol-P in the ER is considered as a rate-
limiting factor in Dol-PP-glycan biosynthesis since an in-
crease in CPT activity and enhanced rate of de novo Dol-P
biosynthesis increases the capacity of LLO synthesis in em-
bryonic rat brain cells (Crick and Waechter 1994).
Regulatory effects of Dol-P-Man on Dol-PP-GlcNAc syn-
thesis have been observed in several systems (e.g. Kean 1982;
Kaushal and Elbein 1985; Shailubhai et al 1988; Kean et al
1994). More recently, a mutual stimulatory effect of Dol-P-
Man and Dol-PP-GlcNAc on their synthesis has been ob-
served in the retinas of embryonic chickens (Kean et al
1999). Moreover, feedback inhibition in the formation of
Dol-PP-GlcNAc was found by the second intermediate of
the pathway, Dol-PP-GlcNAc-GlcNAc. Finally, product inhi-
bition by Dol-PP-GlcNAc itself has been observed (Kean et al
1999).
Another regulatory factor in LLO biosynthesis involves
phosphorylation of Dol-P-Man synthase. In S. cerevisiae, it
was shown that Dol-P-Man synthase activity is regulated by
the cAMP-dependent protein kinase Avia phosphorylation of
S141 (Banerjee et al 2005). Similarly, PKA stimulates Dol-P-
Man synthase activity in mammalian cells (Martinez et al
2006; Baksi et al 2008). In line with these observations
defective glycosylation is observed in protein kinase A defi-
cient Chinese hamster ovary cells (Banerjee et al 2004).
The signaling role of mannose-6-phosphate in LLO degra-
dation was shown in mouse embryonic fibroblasts (Gao et al
2011).
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Conclusions
The current information on dolichol metabolism as outlined
above clearly shows many gaps in our knowledge. Several
known genes still have to be linked to human disease pheno-
types and further studies on unsolved CDG-I patients could
potentially unravel some of the missing genes in dolichol
synthesis. Nevertheless, progress in recent years on human
genetic disease has revealed novel mechanistic insights. The
regulatory aspects in the dolichol pathway and its intercon-
nection in protein networks are still far from being understood.
The fragmented information from various model systems
precludes the mechanism-based interference in dolichol bio-
synthesis defects. Analytical advances have revealed useful
biomarkers of abnormal dolichol metabolites in plasma and/or
urine of SRD5A3-CDG, DHDDS-CDG, and NUS1-CDG
patients. Together with the current recognition of specific
clinical symptoms related to individual gene defects, this
greatly facilitates diagnosis of this group of human defects.
Moreover, this will allow the monitoring of medication re-
sponses, if mechanism-based studies will lead to novel treat-
ments in the future.
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